How does software as a medical device (SaMD) apply to cardiovascular devices?

SaMD can be integrated into cardiovascular care, such as for ECG analysis, treatment planning, or remote monitoring of implanted devices. Such software is regulated independently as a medical device, with its own classification and regulatory requirements based on its intended use and risk, as per FDA guidance on SaMD and EU MDR Annex VIII.

What are the cybersecurity considerations for connected cardiovascular devices?

Connected cardiovascular devices, including pacemakers and ICDs, demand robust cybersecurity measures to protect patient data and device functionality. This involves addressing risks like unauthorized access, data breaches, and malware, in line with FDA guidance on Medical Device Cybersecurity and IMDRF principles for cybersecurity in medical devices.

All terms

Market SegmentsStrategic Landscape

Cardiovascular Devices

Devices for diagnosing, monitoring, or treating cardiovascular disease.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

Spans structural heart (TAVR, mitral, tricuspid), electrophysiology (ablation, mapping, leadless pacing), interventional (stents, IVUS, OCT), and rhythm management (CRT, ICDs, monitors). It is one of the largest device segments by revenue, with heavy investment in minimally invasive and catheter-based therapies. Many products are Class III and need PMA approval with randomized or large single-arm trials. Coverage often depends on national coverage determinations, specialty society guidelines and registries such as the TVT Registry for transcatheter valves.

What the regulation says

Cardiovascular devices, as medical devices, fall under comprehensive regulatory scrutiny, including FDA Premarket Approval (PMA) or 510(k) clearance in the United States and CE marking under the EU Medical Device Regulation (EU MDR) 2017/745 in Europe. These devices are classified based on their risk to patients, which dictates the strictness of regulatory requirements, such as those outlined in 21 CFR Part 820 for Quality System Regulation.

What this means in practice

One of the largest, most R&D-intensive MedTech segments; long evidence cycles and dominant strategics shape competitive dynamics.

Examples

A manufacturer developing a new coronary stent must conduct extensive biocompatibility testing and clinical trials to demonstrate safety and efficacy, fulfilling requirements for a Class III device under the EU MDR.
A company designing a pacemaker needs to implement stringent software validation and cybersecurity controls to meet FDA guidance on cybersecurity for medical devices, given its potential for severe patient harm if compromised.
A firm producing an ECG analysis algorithm must classify its software as a medical device and ensure its performance claims are clinically validated, in accordance with FDA guidance for Software as a Medical Device.

Common pitfalls

•A common pitfall is inaccurately classifying a cardiovascular device, leading to submission of inadequate regulatory documentation or an inappropriate regulatory pathway.
•Manufacturers often underestimate the necessary clinical evidence and long-term follow-up studies required for high-risk cardiovascular devices, causing delays in market authorization.
•Failing to adequately address cybersecurity risks for connected cardiovascular devices, such as pacemakers or defibrillators, can lead to significant safety vulnerabilities and regulatory non-compliance.
•Ignoring post-market surveillance requirements for cardiovascular devices can result in missed opportunities to identify safety issues and fulfill ongoing regulatory obligations.
•Incorrectly defining the device’s intended use can lead to regulatory challenges and limit market access, especially for innovative cardiovascular technologies.

Frequently asked questions

Novel cardiovascular implants typically require a Premarket Approval (PMA) in the United States, which involves a rigorous review of clinical data and manufacturing controls. In the EU, they fall under the highest risk classes (e.g., Class III) and necessitate extensive clinical evaluation and notified body review under the EU MDR.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Regulatory

Premarket Approval(PMA)

FDA's most stringent device marketing application, required for high-risk Class III devices.

Reimbursement

Transitional Coverage for Emerging Technologies(TCET)

CMS pathway providing time-limited Medicare coverage for FDA-designated Breakthrough Devices.

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 4Trade press and expert commentary· 3

Link health: 3 verified· last checked 2026-06-20

American College of Cardiology·1AdvaMed·1MedTech Europe·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Market Segments0 / 38

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Market Segments
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Devices for diagnosing, monitoring, or treating cardiovascular disease.

·One of the largest, most R&D-intensive MedTech segments; long evidence cycles and dominant strategics shape competitive dynamics.
·It is one of the largest device segments by revenue, with heavy investment in minimally invasive and catheter-based therapies.
·Many products are Class III and need PMA approval with randomized or large single-arm trials.

Remember this

Watch out: A common pitfall is inaccurately classifying a cardiovascular device, leading to submission of inadequate regulatory documentation or an inappropriate regulatory pathway.

Related terms

You may also need

Auto-suggested from Market Segments and shared keywords.

All Market Segments terms